Brielmaier Benjamin D
Department of Pharmacy Services, Baylor University Medical Center, Dallas, Texas 75246, USA.
Proc (Bayl Univ Med Cent). 2006 Jan;19(1):54-9. doi: 10.1080/08998280.2006.11928127.
Randomized, placebo-controlled trials have shown that eszopiclone, a newly available nonbenzodiazepine hypnotic, effectively treats the symptoms of insomnia. Its pharmacokinetic and pharmacodynamic parameters are similar to those of the other currently available nonbenzodiazepine hypnotics (i.e., zolpidem and zaleplon). The unique quality of eszopiclone lies in its product labeling. It is not restricted to short-term use, unlike both zolpidem and zaleplon. Dosing of eszopiclone should begin at 2 mg for nonelderly patients and may be initiated at or increased to 3 mg if clinically indicated. The 3-mg nightly dose is more effective at sleep maintenance. Eszopiclone is well tolerated, with the main treatment-emergent side effects being unpleasant taste, headache, and dizziness. No studies comparing eszopiclone with nonpharmacologic insomnia treatments or other hypnotic agents, including zolpidem and zaleplon, are currently available.
随机、安慰剂对照试验表明，新型非苯二氮䓬类催眠药艾司佐匹克隆能有效治疗失眠症状。其药代动力学和药效学参数与其他现有非苯二氮䓬类催眠药（即唑吡坦和扎来普隆）相似。艾司佐匹克隆的独特之处在于其产品标签。与唑吡坦和扎来普隆不同，它不限于短期使用。非老年患者艾司佐匹克隆的起始剂量应为2mg，如有临床指征，可起始剂量为3mg或增加至3mg。每晚3mg的剂量对维持睡眠更有效。艾司佐匹克隆耐受性良好，主要的治疗中出现的副作用为味觉不适、头痛和头晕。目前尚无将艾司佐匹克隆与非药物性失眠治疗方法或其他催眠药物（包括唑吡坦和扎来普隆）进行比较的研究。
